Latest News
  • The intervention will benefit ~60,000 women and children in selected areas of Delhi

  • This initiative will prioritize nutrition outcomes by deepening partnership with the government to strengthen health and ICDS systems to promote evidence-based, sustainable, multi-sectoral actions for improved quality of health and nutrition service.

 

Takeda Biopharmaceuticals India Pvt. Ltd. (formerly known as Baxalta Bioscience India Private Limited) has announced a three-year partnership with Save the Children - Bal Raksha Bharat to strengthen the nutritional well-being of expecting and new mothers as well as children in selected areas of Delhi. Executing through 200 Anganwadi centres, the intervention will strengthen partnership with the government and provide technical assistance in the form of training, capacity-building, and resource support to frontline workers and service providers. The endeavour is expected to improve coverage of quality services related to health and nutrition, improved knowledge and practices of families, and increased household and community-level ownership.

 

Speaking on the partnership, Ruchi Sogarwal, Director-Corporate Affairs, Takeda Biopharmaceuticals India Pvt. Ltd. said, “We look forward to this partnership with Bal Raksha Bharat (globally known as Save the Children) to strengthen maternal and child health in selected areas of Delhi. Creating an environment that results in evidence-based, sustainable, multi-sectoral nutrition actions delivered at scale, this association will deepen partnership with the government to strengthen health and Integrated Child Development Services (ICDS) systems. It will also address the requirement for testing and treatment of anaemia, with an emphasis on pregnant women and school-going or out-of-school adolescents, through Test-Treat-Talk (T3) Anaemia camps. This will be further implemented through engagement with the government and establishing partnerships with local and state-level CSO networks that will be crucial to enabling a favourable environment to create awareness and encourage adequate support around child nutrition.”

 

Adding on the same, Dr. Namrata Jaitli, Director - Policy and Programme Impact, Save the Children (Bal Raksha Bharat) said, "We are delighted to partner with Takeda Biopharmaceuticals India Pvt. Ltd. to play a catalytic role in strengthening the health and nutrition interventions in the urban slums of Delhi. We look forward to leveraging our collective expertise and resources, to create a significant impact in the lives of thousands of women and children. Apart from forging strong partnership with government and community engagements, this intervention will also address the requirement for testing and treatment of anaemia, with an emphasis on pregnant women and school-going or out-of-school adolescents, through Test-Treat-Talk (T3) Anaemia camps. This will also be crucial in improving the health of women and children, offering them a better quality of life.”

 

Takeda Biopharmaceuticals India Pvt. Ltd. will also collaborate with an independent external agency for monitoring of the project and coordinate the evaluations to ensure transparency and effectively achieve the desired outcomes. This partnership aims to positively impact the lives of women and children in targeted zones of Delhi, while also contributing to their overall health and well-being.

 

About Bal Raksha Bharat (Save the Children)

Bal Raksha Bharat works across 15 states of India on issues related to education, health, protection, and humanitarian/DRR needs of children, especially for those who are the most deprived and marginalized. Visit www.savethechildren.in for more information

 

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

 

For more information, visit www.takeda.com.

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

 

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.